RPG Life Sciences will participate in a group meet for analysts and institutional investors on August 25, 2026. The engagement is part of the Antique Healthcare Investor Conference 2026, scheduled to take place physically in Mumbai.

The session will begin at 10:00 am onwards. The company stated that any presentation made during the event will align with the materials available on its website and the stock exchange portals. The date remains subject to change due to exigencies on the part of the company or the host.

Regulatory Disclosure

The announcement was made pursuant to Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Rajesh Shirambekar, Head-Legal & Company Secretary, signed the disclosure on August 20, 2026.

RPG Life Sciences has accepted the resignation of Deepak Shukla as Chief Executive - API Business, effective close of business hours on August 14, 2026. The leadership change coincides with Shukla’s appointment as Chief Executive Officer of RPG Active Pharma Limited, a wholly-owned subsidiary of the parent company, which takes effect on August 15, 2026.

The company disclosed the transition in a filing to the National Stock Exchange of India Limited and BSE Limited on August 15, 2026. The move represents an internal restructuring within the RPG Life Sciences group rather than a departure from the corporate ecosystem.

Regulatory Disclosure Details

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, in its filing.

Shukla submitted his resignation letter to the Managing Director of RPG Life Sciences Limited on August 14, 2026, citing his new appointment as the reason for ceasing to be a Senior Management Personnel of the parent company. Rajesh Shirambekar, Head – Legal & Company Secretary, signed the disclosure letter.